BiotechTubeBiotechTube
Home/Xencor/Celia Eckert, J.D.
CE

Celia Eckert, J.D.

Senior Vice President, General Counsel & Corporate Secretary

Xencor

Therapeutic Areas

OncologyAutoimmune DisordersInfectious Disease

Xencor Pipeline

DrugIndicationPhase
XmAb 14045CancerClinical
XmAb 13676CancerClinical
Ultomiris (ravulizumab-cwvz)PNH, aHUS, gMG, NMOSDApproved/Commercial
Monjuvi (tafasitamab-cxix)Relapsed/Refractory Follicular Lymphoma; r/r DLBCLApproved/Commercial
VibostolimabCancerClinical
PlonmarlimabAutoimmune DiseaseClinical

Leadership Team at Xencor

BI
Bassil I. Dahiyat, Ph.D.
President & Chief Executive Officer, Director
JR
John R. Desjarlais, Ph.D.
Executive Vice President, Research & Chief Scientific Officer
DL
Dane Leone
Executive Vice President & Chief Strategy Officer
BC
Bart Cornelissen
Senior Vice President & Chief Financial Officer
EP
Eric P. Kowack
Senior Vice President, Program Leadership & Alliance Management
MO
Mark Osterman, M.D., M.S.C.E.
Senior Vice President, Clinical Development (Autoimmune)
KR
Kirk Rosemark
Senior Vice President, Regulatory Affairs & Quality Assurance
JS
Jennifer Sandoz
Senior Vice President, Human Resources
View full Xencor profile